Singapore, September 23, 2022 /PRNewswire/ — Hummingbird Bioscience, a data-driven precision biotherapeutic company that discovers and develops innovative biologics for difficult-to-treat diseases, today announced the opening of offices and research facilities at the Singapore Science Park. announced the official opening.Deputy Prime Minister Heng and Minister for Coordinating Economic Policy Sweetieto The opening ceremony was held at The Galen on the 23rd.^rd September 2022Located in The Galen and The Aries buildings, Hummingbird Bioscience’s 40,000-square-foot space houses more than 10 state-of-the-art laboratories integrated with office space.

“This is an important milestone for the Hummingbird Bioscience team, who have come a long way since the company was founded in 2015. Piers Ingram, Ph.D., CEO and Co-Founder of Hummingbird Biosciences. “The Hummingbird Bioscience team currently has 150 people and is responsible for the full spectrum of drug discovery and development activities, from target validation, antibody discovery and bioinformatics to clinical development. We look forward to welcoming more talented teammates on location.”

enterprise Singapore (EnterpriseSG) has closely supported the growth of Hummingbird Bioscience, including the development of its platform technology. SEEDS Capital, the investment arm of EnterpriseSG, also co-invested in the company.Said So Ren OneAssistant Chief Executive Officer (Manufacturing and Engineering) at EnterpriseSG, ” Singapore Since the early investments in biomedical research, the biotechnology innovation scene has grown rapidly. There are now over 40 therapeutic biotechs in the United States. Singapore Many achieve good traction. By 2021, Singapore-based biotech companies will total 860 million Singapore dollarsHummingbird Bioscience is an example of a biotech company that has successfully raised funding and continues to build its capacity to develop clinical-stage assets.This creates new biotech job opportunities Singapore.”

Strengthening in-house capabilities

Pharmacology, mass spectrometry, analytical sciences, production, genomics, discovery, engineering and microbiology labs enable the Hummingbird Bioscience team to further accelerate biotherapeutic research. Integrated with the office space, the proximity allows for a multidisciplinary collaborative environment.

“We continue to build multidisciplinary teams motivated to solve complex scientific problems with creative solutions. Our integrated approach reduces the inherent risks while We aim to accelerate the drug discovery and development process.” Jerome Boyd-KercupPh.D., Chief Scientific Officer and Co-Founder of Hummingbird Biosciences.

Precision Oncology Symposium | X Marks The Spot: Precisely Treating Cancer

Prior to the opening ceremony, Hummingbird Bioscience hosted a precision oncology symposium titled “X Marks The Spot: Treating Cancer with Precision.” Distinguished scientists and oncologists shared their experiences in precision oncology and discussed important recent topics in panel discussions.

speaker:

• Doctor Thomas J. Lynch Jr.Director and Director, Fred Hutchinson Cancer Center
• Professor Chng Wee Joo, Director and Senior Consultant, National university Cancer Institute, Singapore, National university medical system
• Doctor Eric LowinskiChief Medical Officer, Hummingbird Biosciences
• Doctor Jerome Boyd-KercupChief Scientific Officer, Hummingbird Biosciences
• Doctor Piers IngramCEO, Hummingbird Biosciences

About Hummingbird Bioscience

Hummingbird Bioscience is a data-driven precision biotherapy company that discovers and develops innovative biologics for difficult-to-treat diseases. The Hummingbird Bioscience Model combines computational and systems biology with wet lab drug discovery in a multidisciplinary collaborative environment from initial discovery to clinical development. We leverage this integrated approach to target identification and patient selection, enabling teams to increase efficiency in translating new scientific insights while reducing the risks inherent in drug discovery and development. Currently developing his two clinical-stage assets, HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody . Both programs are currently in Phase 1 trials. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new medicines from concept to clinic.

For more information, visit www.hummingbirdbioscience.com and follow Hummingbird Bioscience on LinkedIn. twitterYouTube.

source hummingbird bioscience